TSplus Introduces New Feedback & Roadmap Platform to Enhance the Remote Desktop User Experience 
Think Business, Think Hong Kong strengthens Italy-Hong Kong ties and opens new path for Asian collaboration 
FUTR Announces Q1 2026 Financial Results 
Tenet Reports Third Quarter 2025 Financial Results 
Eguana Announces Third Quarter 2025 Financial Results Virbac : Declaration of the number of shares and voting rights 10/2022
Read moreUltimate Guide: Everything You Need to Know About Industry 4.0 …
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
– SHINE Alzheimer’s Trial Expands to European Sites – – SEQUEL Alzheimer’s Trial Awarded Additional…
Immutep Receives Australian R&D Tax Incentive
Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA, Nov. 14, 2022 (GLOBE NEWSWIRE) —…
ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Continued execution to advance exebacase and CF-370 into new clinical studies YONKERS, N.Y., Nov. 14,…
Revolo Biotherapeutics to Present at TIDES Europe 2022
NEW ORLEANS and LONDON, Nov. 14, 2022 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo” or the…
MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
Financing led by Wellington Management with participation from other leading healthcare funds CARMEL, Ind., Nov….
Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results
— Achieved key clinical and regulatory milestones across clinical pipeline, including the completion of enrollment…
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a…
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update Global trial…
IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update
Conference Call Today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) —…
Universe Pharmaceuticals INC Regains Compliance with Nasdaq Minimum Bid Price Requirement
Ji’an, Jiangxi, China, Nov. 14, 2022 (GLOBE NEWSWIRE) — Universe Pharmaceuticals INC (the “Company”) (Nasdaq:…
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Paltusotine’s Phase 3 PATHFNDR-1 trial in acromegaly fully enrolled and on track for topline data…
Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334
Healthy volunteer study will inform development of 4334 for treatment of hepatitis B virus SOUTH…
Impel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate Update
Trudhesa® nTRx Increased by 27% in Q3 2022 vs. Q2 2022 to 16.7k: Net Product…
Rain Therapeutics to Participate in H.C. Wainwright’s 3rd Annual Precision Oncology Virtual Conference
NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) a…
PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates
PGN-EDO53 NHP Exon Skipping, PGN-EDO45 and PGN-EDO44 Exon Skipping in Wild-Type Human Myoblasts High levels…
Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results
-Timber Received Orphan Designation from European Commission for Lead Asset TMB-001- -Recruitment for the pivotal…
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
FDA clearance of two new INDs: PRT3789 (First-in-class Selective SMARCA2 degrader) and PRT3645 (next generation…
Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
Completed enrollment in the Phase 1 study with novel, broad-spectrum antiviral PB2 candidate CC-42344 for…
Opus Genetics Sponsors Uni-Rare Natural History Study for People with Inherited Retinal Diseases
Largest study to date to characterize natural history of rare retinal diseases RESEARCH TRIANGLE PARK,…